12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Inlyta axitinib: Phase III data

Top-line data from the Phase III AGILE 1051 trial in more than 280 treatment-naïve patients with advanced RCC showed that Inlyta missed the primary endpoint of PFS vs. sorafenib. Specifically, Pfizer said median PFS for Inlyta exceeded the median PFS for sorafenib, but the improvement was not significant. The trial was powered to show a 78% improvement in PFS for Inlyta vs. sorafenib. In a pre-specified subgroup of patients with...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >